Tachycardia, Ventricular Clinical Trial
Official title:
Prospective and Randomized Study to Evaluate Efficacy and Safety of Epicardial Ventricular Tachycardia Ablation Using Contact Force Sensor Irrigated Tip Catheter - Pilot Study
The investigators hypothesized that combined endocardial and epicardial VT ablation using contact sensor irrigated catheter is safe and achieves a lower recurrence rate than endocardial only ablation in ischemic and non-ischemic patients, for this the investigators will randomize 20 patients in two groups, one with endocardial only ablation and other with combined endocardial and epicardial ablation.
Pilot Study Design The investigators will select 20 ischemic or non-ischemic cardiomyopathy
patients with scar related Ventricular tachycardia with indication of VT ablation. After
informed consent, these patients will be randomized to endocardial only (Control Group) or
combined endocardial and epicardial ablation (Treatment Group).
Inclusion Criteria Patients with ischemic and non-ischemic cardiomyopathy and recurrent
sustained monomorphic VT requiring cardioversion or antiarrhythmic drug administration with
≥4 episodes in the previous 6 months despite an ICD or antiarrhythmic drug therapy. Patients
without ICD were eligible after 2 episodes of sustained VT.
Exclusion Criteria Creatinine level >2.5mg/dL; LV ejection fraction <10%; NYHA Class IV;
mobile thrombus on LV; absence of vascular access to the LV; life-expectancy of less than 12
months; previous open-chest cardiac surgical procedure; unstable angina; myocardial
infarction in the last 2 months; severe aortic stenosis; severe mitral regurgitation
secondary to leaflet or chordae rupture; pregnancy and age of less than 18 years old.
Ablation Technique In the patients randomized for combined epicardial and endocardial
ablation, subxyphoid puncture will be performed according to previously described technique.
Following successful epicardial access on the combined epi and endocardial ablation and
following the venous puncture on the endocardial only group, a puncture of femoral artery
will be performed. If the patient has peripheral artery disease, the catheter will be
positioned on the left ventricle through transeptal puncture.
Electroanatomic voltage map will be constructed of the endocardial and epicardial surface.
After map construction, programmed ventricular stimulation of the apex of the RV with S4
extrastimuli will be performed aiming for VT inducibility. If the induced VT is well
tolerated, activation mapping of the VT will be constructed in addition to entrainment
mapping. If the VT is not hemodynamically tolerated, it will be reverted either by Burst or
electrical cardioversion, than substrate modification in the scar combined with pace-mapping
and local abnormal electrograms (late potentials) ablation will be performed. In the patients
in the endocardial only group, only the endocardial surface of the right or left ventricle
will be ablated.
In the combined epicardial and endocardial group, the choice of the surface to be ablated
will be guided by the tachycardia mapping (mesodiastolic and pre-systolic potentials),
extension of the scar, pace-mapping in both surfaces. ECG criteria suggesting epicardial
surface will also be considered to define the epi or endo surface to be ablated.
Following ablation, a repeated programmed ventricular stimulation with S4 will be performed
to evaluated reinducibility of the VT. Additional RF applications can be performed according
to clinical criteria, and the procedure will be considered terminate when no VT is inducible
or by clinical criteria. In the endo only group that endocardial scar could not be observed
or following extensive endocardial ablation the clinical VT still remain inducible, and the
ECG criteria suggests epicardial VT will underwent epicardial mapping and ablation and this
will be considered as a Cross-over.
Outcomes
Primary Outcome:
Safety: The investigators will evaluate the rate of complications related to irrigated tip
catheter use on epicardial surface. It is expected that the combined epicardial and
endocardial ablation group do not present an increase in the rate of catheter-related
complications.
Efficacy: The investigators will evaluate if the procedure was succeeded. The investigators
consider success as follows: (1) Complete Success: prevention of induction of any VT
following ablation; (2) Partial Success: prevention of induction of the clinical VT,
remaining the induction of at least one non-clinical faster VT; (3) Failure: Remaining the
induction of the clinical or initially induced VT.
Secondary Outcome:
Safety: The investigators will evaluate the rate of complications related to the epicardial
access. It is expected a rate of hemopericardium of no more than 20%, with less than 5% rate
of major complications as procedure related death, cardiac surgery due to cardiac perforation
or blood cell transfusion.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01546207 -
Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia
|
N/A | |
Completed |
NCT04070300 -
Physical Activity and Ventricular Arrhythmias
|
N/A | |
Completed |
NCT04075253 -
Acute Effect of One Single Bout of High Intensity Exercise on the Tendency for Ventricular Arrhythmia
|
N/A | |
Completed |
NCT00000531 -
Antiarrhythmics Versus Implantable Defibrillators (AVID)
|
Phase 3 | |
Completed |
NCT00000480 -
Multicenter Unsustained Tachycardia Trial (MUSTT)
|
Phase 3 | |
Completed |
NCT05086510 -
Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
|
N/A | |
Completed |
NCT01940081 -
The Leiden Nonischemic Cardiomyopathy Study
|
||
Recruiting |
NCT01222156 -
Accuracy and Safety Study of the Magnetecs CGCI System for Intracardiac Mapping
|
Phase 1/Phase 2 | |
Terminated |
NCT00749671 -
Bispectral Index Monitoring During Testing in the Electrophysiology Lab
|
N/A | |
Recruiting |
NCT00385749 -
Right Ventricular Defibrillation Lead Select Site Study
|
N/A | |
Completed |
NCT00382928 -
Automatic External Defibrillation Monitoring in Cardiac Arrest
|
Phase 1 | |
Completed |
NCT00279279 -
PREPARE - Primary Prevention Parameters Evaluation
|
N/A | |
Terminated |
NCT00776087 -
European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)
|
N/A | |
Withdrawn |
NCT00510731 -
The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events
|
N/A | |
Completed |
NCT01572246 -
Effects of Monopolar Electrocautery Use During Surgery on Implanted Cardiac Defibrillators
|
N/A | |
Completed |
NCT00170287 -
SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD)
|
Phase 4 | |
Completed |
NCT00147277 -
ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
|
Phase 4 | |
Completed |
NCT00004559 -
Fatty Acid Antiarrhythmia Trial (FAAT)
|
Phase 3 | |
Completed |
NCT00702117 -
Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias
|
Phase 4 | |
Completed |
NCT00232297 -
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS
|
Phase 2 |